Loading…

Solifenacin demonstrates high absolute bioavailability in healthy men

Solifenacin succinate (YM905; Vesicare) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the sugge...

Full description

Saved in:
Bibliographic Details
Published in:Drugs in R&D 2004, Vol.5 (2), p.73-81
Main Authors: Kuipers, Mirjam E, Krauwinkel, Walter J J, Mulder, Hans, Visser, Nico
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573
cites cdi_FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573
container_end_page 81
container_issue 2
container_start_page 73
container_title Drugs in R&D
container_volume 5
creator Kuipers, Mirjam E
Krauwinkel, Walter J J
Mulder, Hans
Visser, Nico
description Solifenacin succinate (YM905; Vesicare) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the suggested starting dose. Single-centre, open-label, randomised, two-period, crossover, single-dose study. Solifenacin was administered orally as a 10 mg dose and intravenously as a 5 mg dose. Oral and intravenous (IV) doses were divided by a washout period of > or =14 days. The study group consisted of 12 healthy young men, aged 20-45 years, nine of whom completed the study. The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence. Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.
doi_str_mv 10.2165/00126839-200405020-00002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66753263</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66753263</sourcerecordid><originalsourceid>FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRb0A0VL4BeQVu4DfdpaoKg8JiQXdW3YyIUZOXOIEqX9PoAVmc6XRuTPSQQhTcsOokreEUKYMLwtGiCCSMFKQedgJWlKqRSGNUQt0nvP7vKVcmTO0oJKV3Ci1RJvXFEMDvatCj2voUp_HwY2QcRveWux8TnEaAfuQ3KcL0fkQw7jHM92Ci2O7xx30F-i0cTHD5TFXaHu_2a4fi-eXh6f13XNRsZKNBdVSq5prVXpZeU0ZB0cMrYxQxEsA4UvlfCkId4pDQ6CpfeOFFzWvnNR8ha4PZ3dD-pggj7YLuYIYXQ9pylYpLTlTfAbNAayGlPMAjd0NoXPD3lJiv63ZX2v2z5r9sTZXr44_Jt9B_V88KuNfIJ1q0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66753263</pqid></control><display><type>article</type><title>Solifenacin demonstrates high absolute bioavailability in healthy men</title><source>Springer Nature - SpringerLink Journals - Fully Open Access</source><creator>Kuipers, Mirjam E ; Krauwinkel, Walter J J ; Mulder, Hans ; Visser, Nico</creator><creatorcontrib>Kuipers, Mirjam E ; Krauwinkel, Walter J J ; Mulder, Hans ; Visser, Nico</creatorcontrib><description>Solifenacin succinate (YM905; Vesicare) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the suggested starting dose. Single-centre, open-label, randomised, two-period, crossover, single-dose study. Solifenacin was administered orally as a 10 mg dose and intravenously as a 5 mg dose. Oral and intravenous (IV) doses were divided by a washout period of &gt; or =14 days. The study group consisted of 12 healthy young men, aged 20-45 years, nine of whom completed the study. The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence. Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.</description><identifier>ISSN: 1174-5886</identifier><identifier>DOI: 10.2165/00126839-200405020-00002</identifier><identifier>PMID: 15293866</identifier><language>eng</language><publisher>New Zealand</publisher><subject>Adult ; Biological Availability ; Cross-Over Studies ; Humans ; Male ; Metabolic Clearance Rate ; Middle Aged ; Muscarinic Antagonists - pharmacokinetics ; Quinuclidines - pharmacokinetics ; Solifenacin Succinate ; Tetrahydroisoquinolines - pharmacokinetics</subject><ispartof>Drugs in R&amp;D, 2004, Vol.5 (2), p.73-81</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573</citedby><cites>FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15293866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuipers, Mirjam E</creatorcontrib><creatorcontrib>Krauwinkel, Walter J J</creatorcontrib><creatorcontrib>Mulder, Hans</creatorcontrib><creatorcontrib>Visser, Nico</creatorcontrib><title>Solifenacin demonstrates high absolute bioavailability in healthy men</title><title>Drugs in R&amp;D</title><addtitle>Drugs R D</addtitle><description>Solifenacin succinate (YM905; Vesicare) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the suggested starting dose. Single-centre, open-label, randomised, two-period, crossover, single-dose study. Solifenacin was administered orally as a 10 mg dose and intravenously as a 5 mg dose. Oral and intravenous (IV) doses were divided by a washout period of &gt; or =14 days. The study group consisted of 12 healthy young men, aged 20-45 years, nine of whom completed the study. The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence. Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.</description><subject>Adult</subject><subject>Biological Availability</subject><subject>Cross-Over Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Muscarinic Antagonists - pharmacokinetics</subject><subject>Quinuclidines - pharmacokinetics</subject><subject>Solifenacin Succinate</subject><subject>Tetrahydroisoquinolines - pharmacokinetics</subject><issn>1174-5886</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpFkMtOwzAQRb0A0VL4BeQVu4DfdpaoKg8JiQXdW3YyIUZOXOIEqX9PoAVmc6XRuTPSQQhTcsOokreEUKYMLwtGiCCSMFKQedgJWlKqRSGNUQt0nvP7vKVcmTO0oJKV3Ci1RJvXFEMDvatCj2voUp_HwY2QcRveWux8TnEaAfuQ3KcL0fkQw7jHM92Ci2O7xx30F-i0cTHD5TFXaHu_2a4fi-eXh6f13XNRsZKNBdVSq5prVXpZeU0ZB0cMrYxQxEsA4UvlfCkId4pDQ6CpfeOFFzWvnNR8ha4PZ3dD-pggj7YLuYIYXQ9pylYpLTlTfAbNAayGlPMAjd0NoXPD3lJiv63ZX2v2z5r9sTZXr44_Jt9B_V88KuNfIJ1q0A</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Kuipers, Mirjam E</creator><creator>Krauwinkel, Walter J J</creator><creator>Mulder, Hans</creator><creator>Visser, Nico</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Solifenacin demonstrates high absolute bioavailability in healthy men</title><author>Kuipers, Mirjam E ; Krauwinkel, Walter J J ; Mulder, Hans ; Visser, Nico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Biological Availability</topic><topic>Cross-Over Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Muscarinic Antagonists - pharmacokinetics</topic><topic>Quinuclidines - pharmacokinetics</topic><topic>Solifenacin Succinate</topic><topic>Tetrahydroisoquinolines - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuipers, Mirjam E</creatorcontrib><creatorcontrib>Krauwinkel, Walter J J</creatorcontrib><creatorcontrib>Mulder, Hans</creatorcontrib><creatorcontrib>Visser, Nico</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs in R&amp;D</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuipers, Mirjam E</au><au>Krauwinkel, Walter J J</au><au>Mulder, Hans</au><au>Visser, Nico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Solifenacin demonstrates high absolute bioavailability in healthy men</atitle><jtitle>Drugs in R&amp;D</jtitle><addtitle>Drugs R D</addtitle><date>2004</date><risdate>2004</risdate><volume>5</volume><issue>2</issue><spage>73</spage><epage>81</epage><pages>73-81</pages><issn>1174-5886</issn><abstract>Solifenacin succinate (YM905; Vesicare) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10 mg, which is twice the suggested starting dose. Single-centre, open-label, randomised, two-period, crossover, single-dose study. Solifenacin was administered orally as a 10 mg dose and intravenously as a 5 mg dose. Oral and intravenous (IV) doses were divided by a washout period of &gt; or =14 days. The study group consisted of 12 healthy young men, aged 20-45 years, nine of whom completed the study. The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence. Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.</abstract><cop>New Zealand</cop><pmid>15293866</pmid><doi>10.2165/00126839-200405020-00002</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1174-5886
ispartof Drugs in R&D, 2004, Vol.5 (2), p.73-81
issn 1174-5886
language eng
recordid cdi_proquest_miscellaneous_66753263
source Springer Nature - SpringerLink Journals - Fully Open Access
subjects Adult
Biological Availability
Cross-Over Studies
Humans
Male
Metabolic Clearance Rate
Middle Aged
Muscarinic Antagonists - pharmacokinetics
Quinuclidines - pharmacokinetics
Solifenacin Succinate
Tetrahydroisoquinolines - pharmacokinetics
title Solifenacin demonstrates high absolute bioavailability in healthy men
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A49%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Solifenacin%20demonstrates%20high%20absolute%20bioavailability%20in%20healthy%20men&rft.jtitle=Drugs%20in%20R&D&rft.au=Kuipers,%20Mirjam%20E&rft.date=2004&rft.volume=5&rft.issue=2&rft.spage=73&rft.epage=81&rft.pages=73-81&rft.issn=1174-5886&rft_id=info:doi/10.2165/00126839-200405020-00002&rft_dat=%3Cproquest_cross%3E66753263%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c292t-17576d3769b5cb7123ea081c8460b5ee4b96ab9403a63ef0efdbfb4b4d3ca573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66753263&rft_id=info:pmid/15293866&rfr_iscdi=true